The pharmaceutical company AI-Therapeutics (Guilford, CT, USA) has acquired the preclinical drug candidates EC-8042 and EC-70124 in the course of the insolvency proceedings EntreChem was experiencing since February of last... read more →
EntreChem closed a financing round totaling 1 million EUR ($1.25M) with existing shareholders of the company. This all-private funding significantly strengthens the capacities of research and development of the biotech... read more →
EntreChem closed a financing round thanks to a mix of private and public funding, in a deal that significantly strengthens the capacities of research and development of the biotech company.... read more →
The Centre for the Development of Industrial Technology (CDTI) has awarded EntreChem with a NEOTEC-2 grant, consisting on a special loan (a reimbursable loan) of 658.050 EUR for development of... read more →
EntreChem has signed an agreement with The Centre for the Development of Industrial Technology (CDTI) consisting on a reimbursable loan of 400,000 EUR within the NEOTEC program for promotion of... read more →
EntreChem has signed an agreement with the “Sociedad Regional de Promoción” of the Principality of Asturias for a special loan (a “participative loan”) to finance start-up activities of EntreChem. This... read more →